In the Philippines, access to comprehensive genomic profiling (CGP), circulating tumor DNA (ctDNA), and cell-free DNA (cfDNA) ...

"Symptoms of ovarian cancer are vague, non-specific, and occur with a variety of conditions," Dr. Priyal Dholakiya, MD, a ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Anixa Biosciences receives approval of protocol amendment for ovarian cancer CAR-T clinical trial: San Jose, California Friday, February 21, 2025, 18:00 Hrs [IST] Anixa Bioscience ...

Find Ovarian Cancer Research stock video, 4K footage, and other HD footage from iStock. Get higher quality Ovarian Cancer Research content, for less—All of our 4K video clips are the same price as HD.

At just 31 years old, Cameron Gourley had just gotten married when she noticed a lump during her typical self-exam.

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ ...

A Pap smear or Pap test is a screening test for cervical cancer. There’s currently no easy and reliable early screening test for ovarian cancer. A Pap smear or Pap test doesn’t help doctors ...

Previously, Anixa and Moffitt had secured a single patient IND approval for an additional dose for a patient whose biopsy showed ... advance the treatment of ovarian cancer with CAR-T therapy.